Phase 2 N=20 A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer
Kidney Cancer
Primary: Percentage of Participants With Response — 0; 15; 65; 10 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=37 A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...
Head and Neck Neoplasms · Pheochromocytoma · Colorectal Neoplasms
Primary: Response Rate — 0; 0; 26; 11 Participants
Phase 2 N=30 Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer
Renal Cell Carcinoma
Primary: Progression-free Survival — 8.3 months
Phase 1 N=12 Single-Dose Study to Evaluate the PKs of Pretomanid in Participants With Renal Impairment Compared to Participants With Normal Renal Function
Renal Impairment · Tuberculosis
Primary: Fold Change in Pretomanid AUC(0-last) in Participants With Renal Impairment as Compared to Matched Healthy Controls — 77130; 63600; 62660 ng*h/mL
Phase 2 N=31 A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease
Non Clear Cell Renal Cell Carcinoma (nccRCC)
Primary: Objective Response Rate (ORR) — 25.8 percentage of participants
Phase 2 N=72 Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma
Renal Cell Carcinoma · Neoplasm Metastases
Primary: To Determine the Overall Response Rate of Combination Therapy With Gemcitabine and Sunitinib in Sarcomatoid and/or Poor-risk mRCC Patients as First Line Therapy. — 25…
Phase 2 N=138 A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
Oesophageal Squamous Cell Carcinoma · Gastric Cancer · Hepatocellular Carcinoma
Primary: Cohort A: Objective Response Rate (ORR) — 20.0 percentage of participants
Phase 2 N=41 Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
Renal Cell Carcinoma · Kidney Cancer
Primary: 4-month Progression-Free Survival Rate — 65 percentage of participants — p=0.081
Phase 2 N=67 RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
Neuroendocrine Carcinoma · Islet Cell Carcinoma
Primary: Progression Free Survival (PFS) — 60 Weeks
Phase 2 N=45 SLM + Axitinib for Clear Cell RCC
Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)
Primary: Incidence of Adverse Events (AE) Per CTCAE 4.03 — 3; 5; 7; 20 Participants
Phase 1 N=16 Study of Oral Lasmiditan in Participants With Normal and Impaired Renal Function
Migraine
Primary: Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) — 259; 293 nanogram per milliliter (ng/mL)
N/A N=177 mHealth Behavioral Cancer Pain Intervention for Medically Underserved Patients
Breast Cancer
Primary: Pain Severity as Measured by the Brief Pain Inventory (BPI) — 4.71; 4.51; 3.52; 4.69 score on a scale
Phase 1 N=61 Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
Solid Tumors
Primary: Dose Escalation Cohort (Excluding Once Weekly Avelumab 10 mg/kg Cohort): Number of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0; 0; 0; 1 Participants
Phase 2 N=13 Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer
Renal Cell Carcinoma
Primary: The Number of Patients With Grade 3 and Grade 4 Adverse Events of Interest — 0 Participants
Phase 1 N=1,260 Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)
Cancer, Solid Tumor
Primary: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0…